Contego Medical, Inc. appears in FDA device records as the applicant for a carotid stent system and a separate embolic protection clearance, with the agency's device records listing the firm at 3801 Lake Boone Trail, Suite 100, Raleigh, North Carolina. The documented portfolio in the supplied filings covers two regulatory pathways: an original premarket approval and a panel-track supplement for the stent system, plus a 510(k) for the embolic protection system. The company's own product page states that Medtronic is now the sole distributor of Neuroguard IEP in the United States and that page content is superseded by Medtronic's material. [1][2][5]

The carotid stent approval and its panel supplement

P240009 was approved on October 11, 2024, according to the FDA approval letter addressed to Contego Medical and signed for the Director of the Division of Coronary and Peripheral Intervention Devices. The Summary of Safety and Effectiveness Data identifies the device as the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilatation Balloon System with Integrated Embolic Protection, product code NIM, and records the applicant's address in Raleigh, North Carolina. [7][9]

A later supplement, P240009/S006, carries a decision date of November 4, 2026, with supplement type listed as Panel and a receipt date of September 29, 2025. Its approved indications describe use of the Neuroguard IEP Direct 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection in conjunction with the Neuroguard IEP Embolic Protection System, and include post-dilation of the stent component with simultaneous capture and removal of embolic material. [2]

The embolic protection clearance

K260600 covers the Neuroguard IEP Embolic Protection System under product code NTE, device class 2, regulation number 870.1250, in the cardiovascular advisory committee. The record shows a receipt date of February 24, 2026, a decision date of November 4, 2026, decision code SESE for substantially equivalent, traditional clearance type, and a summary statement. The openFDA device name associated with the product code is Temporary Carotid Catheter For Embolic Capture. [1]

What the supplied filings show, and what they do not

The supplied collection holds three linked records as of the snapshot: one 510(k) and two premarket approvals, with decision counts of one SESE and two APPR. The smaller record sample of three entries carries the same counts, one SESE and two APPR. These figures describe the supplied filings only and are not measures of total company sales, total portfolio or safety performance. [1][2][3]

The original P240009 approval describes the device as indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy, and states that the Neuroguard IEP System should always be used in conjunction with an available primary distal embolic protection device as described in the instructions for use. The later supplement describes use with the Neuroguard IEP Embolic Protection System instead. Both statements are regulatory scope language from FDA records, not clinical guidance. [2][3]

Company identity and distribution

Contego Medical's Neuroguard IEP page states that Medtronic is now the sole distributor of the product in the United States and that claims or product information on the page are superseded by content on Medtronic's site. The same page lists Neuroguard IEP under carotid products and Excipio Thrombectomy and Vanguard IEP under peripheral vascular products, and identifies Paladin, Neuroguard IEP, Vanguard IEP, Excipio, Integrated Embolic Protection and FlexRing as its trademarks or registered trademarks. No parent, ownership structure or headquarters is verified in the public documents beyond the applicant address in FDA filings. [5]